Technology evaluation: PK1, Pfizer/Cancer Research UK.
Pfizer (formerly Pharmacia) is collaborating with Cancer Research UK in developing PK1 (FCE-28068) for the potential treatment of various cancers. PK1 is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker, which is currently undergoing phase II trials for breast, non-small-cell lung and colon cancers.
Bilim
Vladimir
V
Department of Urology, Niigata University School of Medicine, Niigata University, Asahimachi 1, Niigata 951-8510, Japan. vbilim@med.niigata-u.ac.jp
D000178:Acrylamides / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005947:Glucose / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011355:Prodrugs / Q000378:metabolism
D000178:Acrylamides; D000970:Antineoplastic Agents; D011355:Prodrugs; C482378:N-(2-hydroxypropyl)methacrylamide co-polymer-doxorubicin conjugate; D004317:Doxorubicin; D005947:Glucose